All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target

June 9th 2025

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Dr Rugo on QOL Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 9th 2025

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

SERENA-6 Introduces Potential New Paradigm of Early ESR1 Mutation Detection to Delay Progression in HR+ Breast Cancer

June 9th 2025

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List

June 9th 2025

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

Five Under 5: Top Oncology Videos for the Week of 6/1

June 8th 2025

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

RET Inhibitor Rechallenge Demonstrates Activity in Previously Treated NSCLC

June 8th 2025

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

The OncFive: Top Oncology Updates for the Week of 6/1

June 7th 2025

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

Padeliporfin VTP Shows Safety, Clinical Activity in Upper Tract Urothelial Cancer

June 7th 2025

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Perioperative Sacituzumab Govitecan Plus Pembrolizumab Is Safe, Active in MIBC

June 6th 2025

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer

June 6th 2025

Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Mittendorf on Expanding ASCO’s Mission Through Research Advocacy and Global Collaboration

June 6th 2025

Elizabeth Mittendorf, MD, PhD, MHCM, discusses advancing ASCO’s mission through research advocacy, global collaboration, and a commitment to equity.

Acalabrutinib-Based Regimens Receive European Approval in Frontline CLL

June 6th 2025

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

FDA Receives NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

June 6th 2025

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

Pirtobrutinib Adds Effective Option to CLL Treatment Landscape, Underscoring Treatment Selection Considerations

June 6th 2025

Nitin Jain, MD, discusses the role pirtobrutinib has played in the chronic lymphocytic leukemia treatment paradigm.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma

June 6th 2025

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia

June 5th 2025

Kanwarpal S. Kahlon, MD, discusses the implications of the availability of generic eltrombopag for immune thrombocytopenia and severe aplastic anemia.

Bispecific Antibodies Improve TTNT and Reshape R/R Follicular Lymphoma Management

June 5th 2025

Vivek Patel, MD, discusses the growing body of data supporting the use of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.

Pancreatic Cancer Spreads to Liver or Lung Thanks to This Protein

June 5th 2025

A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL

June 5th 2025

Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.